NUREXONE BIOLOGIC INC. Net Assets
NUREXONE BIOLOGIC INC. net assets. Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has net assets worth €2.76 Million EUR (≈ $3.22 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.08 Million ≈ $4.77 Million USD) and total liabilities (€1.32 Million ≈ $1.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NUREXONE BIOLOGIC INC. net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.76 Million |
| % of Total Assets | 67.55% |
| Annual Growth Rate | 23.72% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 359.78 |
Net Assets of NUREXONE BIOLOGIC INC. (2021–2025)
Net assets of NUREXONE BIOLOGIC INC. from 2021 to 2025. This chart illustrates how NUREXONE BIOLOGIC INC.'s net assets have evolved over time, based on quarterly financial data. See J90 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for NUREXONE BIOLOGIC INC. (2021–2025)
The table below shows the annual net assets of NUREXONE BIOLOGIC INC. from 2021 to 2025. For live market cap and overall valuation, see NUREXONE BIOLOGIC INC. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.76 Million ≈ $3.22 Million |
+56.62% |
| 2024-12-31 | €1.76 Million ≈ $2.06 Million |
+831.75% |
| 2023-12-31 | €189.00K ≈ $220.96K |
-90.98% |
| 2022-12-31 | €2.10 Million ≈ $2.45 Million |
+78.08% |
| 2021-12-31 | €1.18 Million ≈ $1.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NUREXONE BIOLOGIC INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2323500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
NUREXONE BIOLOGIC INC. Net Assets Breakdown (December 2025)
NUREXONE BIOLOGIC INC. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €28.24 Million | 1024.00% |
| Total Equity | €2.76 Million | 100.00% |
NUREXONE BIOLOGIC INC. Competitors by Market Cap
The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Commerce Resources Corp.
V:CCE
|
$30.80 Million |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
$30.80 Million |
|
Nureca Limited
NSE:NURECA
|
$30.80 Million |
|
Sun Race Sturmey-Archer Inc
TW:1526
|
$30.81 Million |
|
Italy Innovazioni SpA
PA:MLITN
|
$30.78 Million |
|
Autech Corporation
KQ:067170
|
$30.77 Million |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
$30.77 Million |
|
Blue Star Helium Ltd
AU:BNL
|
$30.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NUREXONE BIOLOGIC INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,761,000 to 2,758,000, a change of 997,000 (56.6%).
- Net loss of 6,384,000 reduced equity.
- New share issuances of 2,905,000 increased equity.
- Other factors increased equity by 4,476,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.38 Million | -231.47% |
| Share Issuances | €2.90 Million | +105.33% |
| Other Changes | €4.48 Million | +162.29% |
| Total Change | €- | 56.62% |
Book Value vs Market Value Analysis
This analysis compares NUREXONE BIOLOGIC INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.41x to 9.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.03 | €0.29 | x |
| 2022-12-31 | €0.05 | €0.29 | x |
| 2023-12-31 | €0.00 | €0.29 | x |
| 2024-12-31 | €0.02 | €0.29 | x |
| 2025-12-31 | €0.03 | €0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NUREXONE BIOLOGIC INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -231.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.48x
- Recent ROE (-231.47%) is above the historical average (-594.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -139.93% | 0.00% | 0.00x | 2.41x | €-1.76 Million |
| 2022 | -389.74% | 0.00% | 0.00x | 1.33x | €-8.38 Million |
| 2023 | -1925.40% | 0.00% | 0.00x | 11.48x | €-3.66 Million |
| 2024 | -286.37% | 0.00% | 0.00x | 1.39x | €-5.22 Million |
| 2025 | -231.47% | 0.00% | 0.00x | 1.48x | €-6.66 Million |
Industry Comparison
This section compares NUREXONE BIOLOGIC INC.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NUREXONE BIOLOGIC INC. (J90) | €2.76 Million | -139.93% | 0.48x | $30.78 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more